Highlights•AR is a clinically fully validated target for treatment of human prostate
cancer.•PROTAC AR degraders overcome common resistance mechanisms developed …

Nuclear receptors (NRs) are transcription factors actively involved in many aspects of human
physiology and pathology, serving as sensors of stimuli, master regulators of downstream …

Prostate cancer is a leading cause of cancer-related death in men worldwide. Aberrant
signaling in the androgen pathway is critical in the development and progression of prostate …

Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

Phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in the first step of the
serine synthesis pathway (SSP), is overexpressed in multiple types of cancers. The …

Checkpoint immunotherapy has yielded meaningful responses across many cancers but
has shown modest efficacy in advanced prostate cancer. B7 homolog 3 protein (B7 …

Sex steroids are major promoters of the growth of breast and prostate cancers. This Review
by Poutanen et al. describes the development of treatments for these cancer types that act to …

Prostate cancer (PCa) is a prevalent malignancy that occurs primarily in old males. Prostate
tumors in different patients manifest significant inter-patient heterogeneity with respect to …

The functional role of microRNA-375 (miR-375) in the development of prostate cancer (PCa)
remains controversial. Previously, we found that plasma exosomal miR-375 is significantly …

In prostate cancer, resistance to the antiandrogen enzalutamide (Enz) can occur through
bypass of androgen receptor (AR) blockade by the glucocorticoid receptor (GR). In contrast …